Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 11/24 11:31:15 am
80.27 CHF   +0.84%
10:14aGLOBAL MARKETS LIVE: Tesla, Best Buy, Qantas…
07:51aNOVARTIS AG : Goldman Sachs reaffirms its Buy rating
MD
01:47aNOVARTIS : to Repurchase Up to $2.5 Billion in Shares
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • The group usually releases earnings worse than estimated.
  • The company's enterprise value to sales, at 4.08 times its current sales, is high.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVARTIS AG-13.38%198 168
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-3.77%283 004
MERCK & CO., INC.-11.73%203 111
PFIZER INC.-6.79%202 993
ABBVIE INC.15.41%180 396
NOVO NORDISK A/S8.99%154 949
BRISTOL-MYERS SQUIBB COMPAN..-3.54%139 924
ASTRAZENECA PLC5.17%139 522
ELI LILLY AND COMPANY9.09%129 986
AMGEN INC.-7.82%129 370
SANOFI-6.17%124 806
GLAXOSMITHKLINE PLC-23.22%90 365
CHUGAI PHARMACEUTICAL CO., ..31.88%69 694
JIANGSU HENGRUI MEDICINE CO..18.08%69 168
DAIICHI SANKYO COMPANY, LIM..46.76%65 825
More Results
Financials (USD)
Sales 2020 49 193 M - -
Net income 2020 8 405 M - -
Net Debt 2020 19 822 M - -
P/E ratio 2020 23,6x
Yield 2020 3,63%
Capitalization 198 B 199 B -
EV / Sales 2020 4,44x
EV / Sales 2021 4,06x
Nbr of Employees 110 000
Free-Float 86,9%
Upcoming event on NOVARTIS AG
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes